CINCINNATI, OH, February 7, 2019 – Callitas Health Inc., (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”) an integrated clinical-stage pharmaceutical development, OTC consumer goods marketing and cannabis delivery development company, announced today that it has signed a letter of intent with NuEthix, LLCto manufacture and supply proprietary formulations of CannaStrip products for retail sale in the United States through the nutrition and fitness channel.

“The Callitas sublingual CBD is a very exciting product that is perfectly in line with our mission of offering only high-quality products that provide true therapeutic benefits for our customers,” said Stephaney Theobald, co-owner and CFO of NuEthix, LLC. “We have a passion for helping others and our main goal is to help them feel better. We feel strongly that this new product will allow us to provide another avenue to accomplish this.”

Callitas, which focuses on developing innovative technologies for both OTC and drug markets, is focused on bringing pharmaceutical best practices to the cannabis space through controlled dosing, improved bioavailability and advanced manufacturing techniques. The Company also develops ground-breaking technologies for weight management and female health and wellness.

“Our agreement with NuEthix for CannaStrips in the nutrition and fitness segment is just one more step toward making Callitas a stronger player in the rapidly expanding cannabinoid market,” said James M. Thompson, CEO of Callitas. “We’re looking forward to this mutually-beneficial partnership and working with NuEthix to develop advanced, proprietary formulations of the CannaStrip technology for their customers.”

About NuEthix, LLC:NuEthix Formulations is a supplement company located in Cincinnati, OH, based on 4 principles of integrity, truth, honesty and transparency; our motto is Unifying Health and Performance. The owners are Jason Theobald of Scoobyprep.com, Stephaney Theobald of Nattynutrition.com and Vince Pitstick with Nutrition Dynamic. Together they have over 40 years experience in the fitness industry working with top level athletes. They have seen what issues arise in athletes who push themselves to the be the best, and it was analyzing these very issues that created the need for a nutraceutical company who blends foundational health with performance.  They knew they could bring products to market to help not only their clients be successful, but everyone else as well. Currently they have a line of 10 products that works as a system to improve foundational health, www.nuethix.com.

About Callitas Health: Formed in early 2015, Callitas Health Inc. is an integrated clinical-stage pharmaceutical development, OTC consumer goods marketing and cannabis delivery development company, focused on developing innovative technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J’s LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive(www.toconceive.com), and is in the research and development and business development process for its other OTC products, CannaStrips and orphan drug technologies. For more information visit www.callitas.com.

Contacts:

Callitas Health:
James Thompson, CEO, or
Callitas Investor Relations
Phone: +1 (859) 868-3131

TraDigitalIR:
Investor Relations – Kevin McGrath, Managing Director
Phone:  +1 (646) 418-7002

Notice regarding Forward Looking Statements:This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval and the commercialization of the rights to the Company’s biomedical & drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.thecse.com.  Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies

Notice regarding investigational devices:CannaMint Strips, C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials.  Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body. Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements.